Translate Bio Announces First Quarter 2019 Financial Results and Provides Corporate Update
Telesis Bio, Inc. (TBIO)
US:NASDAQ Investor Relations:
businesswire.com/news/home/20170630005160/en/precipio-diagnostics-transgenomic-complete-merger
Company Research
Source: GlobeNewswire
-- Completed dosing in single-ascending dose portion of Phase 1/2 clinical trial in cystic fibrosis; data expected 3Q19 -- LEXINGTON, Mass., May 09, 2019 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced financial results for the first quarter ended March 31, 2019 and reviewed recent corporate achievements and updates. “This quarter, we have continued to focus on progressing our programs for rare genetic diseases while also advancing our mRNA therapeutic (MRT) platform to fuel future pipeline programs,” said Ronald Renaud, chief executive officer of Translate Bio. “We are excited to share that we have completed dosing in the single-ascending dose portion of the ongoing Phase 1/2 clinical trial for MRT5005 in patients with cystic fibrosis and anticipate reporting interim data from this tria
Show less
Read more
Impact Snapshot
Event Time:
TBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TBIO alerts
High impacting Telesis Bio, Inc. news events
Weekly update
A roundup of the hottest topics
TBIO
News
- Telesis Bio Inc. announces strategic focus on game-changing Gibson SOLA enzymatic DNA synthesis (EDS) platform and BioXp mRNA solutions and announces new leadership [Yahoo! Finance]Yahoo! Finance
- Telesis Bio Inc. announces strategic focus on game-changing Gibson SOLA enzymatic DNA synthesis (EDS) platform and BioXp mRNA solutions and announces new leadershipGlobeNewswire
- Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewswire
- Telesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial ResultsGlobeNewswire
TBIO
Earnings
- 3/28/24 - Miss
TBIO
Sec Filings
- 4/18/24 - Form 8-K
- 4/9/24 - Form PRE
- 4/8/24 - Form 8-K
- TBIO's page on the SEC website